Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dry powder tobramycin via Cyclops in children with cystic fibrosis
NL-OMON50074Phase 2Active, not recruiting
- Sponsor
- University Medical Center Groningen
- Start
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tobramycin in cystic fibrosis (CF) and chronic Pseudomonas aeruginosa infection, sponsored by University Medical Center Groningen. Primary endpoint: AUC0 to 8-12 hours. Started Aug 2018; status: active, not recruiting.
02
Drugs
tobramycin
03
Conditions
cystic fibrosis (CF)chronic Pseudomonas aeruginosa infection
Beyond the preview
Go deeper on NL-OMON50074.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50074.